Notes on Study NCT03248479

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 430
Joined: Fri Jul 20, 2018 5:13 pm

Notes on Study NCT03248479

Post by biopearl123 » Wed Sep 16, 2020 6:09 pm

Magrolimab mono therapy or Magrolimab in combination with Azacitidine in patients with hematological malignancies:

Study expanded from 96 patients to to 257. Additional primary end point added: 8 week TI in patients with low risk MDS.

Additional thoughts: CD 47 is expressed as disease progress with lower CD 47 (about 16%) in low risk to 60% in high risk. CD 47 expression may actually be lower in MF progenitor cells. Still trying to work out where in the treatment scheme this combination might fit. Some specific genetic mutations may selectively benefit. Imetelstat may still have broad potential effects. Thought? bp

Post Reply